Sean Kaufman
Primary Podiatric Medicine · Kenilworth, NJNPI 1821091018
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Smith+Nephew at 38.5% of the total. Reporting peaked in 2019 at $138 and has fallen 75.5% since, to $34 in 2025. That places this record below the midpoint for primary podiatric medicine clinicians in NJ, where the typical reported total is $548.
Across 11 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$71
- Sandoz$51
- Paragon 28, Inc.$22
- Integra Lifesciences Corporation$15
- Merck$12
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$12
What the payments were for
- Food & beverage$184100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 4 | $71 |
| Sandoz | 3 | $51 |
| Paragon 28, Inc. | 1 | $22 |
| Integra Lifesciences Corporation | 1 | $15 |
| Merck | 1 | $12 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $12 |
How this compares
$184 in reported general payments places this provider in the 35th percentile of 45 primary podiatric medicine providers in New Jersey.
See all primary podiatric medicine providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ciclopirox | 39 | $2,182 |
| Clobetasol Propionate | 18 | $1,067 |
| Econazole Nitrate | 20 | $805 |
| Ketoconazole | 22 | $535 |
| SsdSilver Sulfadiazine | 16 | $333 |
| Gabapentin | 31 | $238 |
| Mupirocin | 24 | $203 |
| Terbinafine Hcl | 13 | $149 |
| Methylprednisolone | 26 | $143 |
| Naproxen | 12 | $83 |
| Meloxicam | 28 | $82 |
| Cyclobenzaprine Hcl | 11 | $60 |
Paid to pharmacies, not to this prescriber.
Other primary podiatric medicine in Kenilworth
- Andrew BloomEnglewood$14K
- Paul KleinWayne$6K
- Jessica AddeoHowell$5K
- Alicia LaiLinwood$5K
- Adenike SonaikeFair Lawn$5K
- Harvey KarpoWoodbury$5K
- Melissa ShinderMount Laurel$3K
- Richard MunozDover$3K
- Stephanie ExleyWoodbury$2K
- Richard FilipekGarfield$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.